Database

Startups

Main Industry
Health Care
Main Product/Service
1. Cell Therapy
2. Clinical trial
3. MCRcI®
4. MiSaver®
Founded Year
2011
Unified Business No.
53523105
Status
Active
Number of Employees
0
Total Paid-in Capital
200,544,220 (NT$)
Location of Company
Taiwan , Tainan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
HONYA Medical is a cutting-edge stem cell pharmaceutical company dedicated to developing advanced regenerative therapies. Focused on combating cardiovascular diseases and other degenerative conditions, HONYA creates state-of-the-art stem cell products that are ethically sourced and manufactured under strict GTP/GMP standards. Their pioneering technologies enable the cultivation, modification, and use of stem cells to repair and regenerate tissues, offering new hope for patients worldwide. With a mission to redefine health through innovation, HONYA is at the forefront of transforming the future of medicine.



More ↓

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

ACEPODIA BIOTECHNOLOGIES, LIMITED

1. ACC (Antibody-Cell Conjugation) technology
2. γδ2 T cell therapy
3. ACE1831
4. ACE2016
5. ACE1708

CytoArm CO., LTD.

CytoArm’s flagship technology is its Armed-T™ cell therapy, which uses a non-viral manufacturing process to produce tumor-specific T cells with over 90% purity in around 10 days. The platform is highly adaptable, with the potential to develop treatments f